Haemonetics to acquire OpSens for more than $250M, expanding cardiology device portfolio

Haemonetics (NYSE: HAE) + today announced a definitive agreement to acquire cardiology-focused technology developer OpSens.

Boston-based Haemonetics will acquire all outstanding shares of Opsens for CAD $2.90 in an all-cash transaction that will have a fully diluted equity value of approximately $253 million USD. The transaction is expected to close by the end of January 2024.

Opsens develops optical technology for use in interventional cardiology. Its products include the SavvyWire and OptoWire.

SavvyWire is a sensor-guided 3-in-1 guide wire for TAVR procedures that acts as a pacing and pressure monitoring wire that advances the workflow of the procedure for shorter hospital stays. OptoWire is a pressure guide wire that aims to improve clinical outcomes by accurately and consistently measuring fractional flow reserve (FFR) and diastolic pressure ratio to help clinicians in the diagnosis and treatment of coronary …
Read more
  • 0